Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 842

1.

Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.

Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F, Regulski M.

Exp Clin Endocrinol Diabetes. 2006 Oct;114(9):527-32.

PMID:
17115351
2.

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.

PMID:
18158078
4.

Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.

Kvapil M, Swatko A, Hilberg C, Shestakova M.

Diabetes Obes Metab. 2006 Jan;8(1):39-48.

PMID:
16367881
5.

Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).

Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A.

Diabetes Obes Metab. 2009 Jan;11(1):27-32. Epub 2007 Oct 17.

PMID:
17941873
6.

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A; INITIATE Study Group..

Diabetes Care. 2005 Feb;28(2):260-5.

PMID:
15677776
7.

Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT.

Strojek K, Bebakar WM, Khutsoane DT, Pesic M, Smahelová A, Thomsen HF, Kalra S.

Curr Med Res Opin. 2009 Dec;25(12):2887-94. doi: 10.1185/03007990903354674.

PMID:
19821654
8.

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.

Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H.

Diabetes Care. 2005 Feb;28(2):254-9.

PMID:
15677775
11.

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.

Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.

Ann Intern Med. 2008 Oct 21;149(8):531-9.

PMID:
18936501
13.

Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).

Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R.

Diabetes Obes Metab. 2006 Jan;8(1):58-66.

PMID:
16367883
15.

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.

PMID:
16505505
17.

Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.

Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH; Lispro Mixture-Glargine Study Group..

Clin Ther. 2004 Dec;26(12):2034-44. Erratum in: Clin Ther. 2005 Jul;27(7):1112.

PMID:
15823767
18.

Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.

Davidson JA, Liebl A, Christiansen JS, Fulcher G, Ligthelm RJ, Brown P, Gylvin T, Kawamori R.

Clin Ther. 2009 Aug;31(8):1641-51. doi: 10.1016/j.clinthera.2009.08.011.

PMID:
19808125
19.

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S.

Diabetes Obes Metab. 2009 Feb;11(2):157-66. doi: 10.1111/j.1463-1326.2008.00994.x. Erratum in: Diabetes Obes Metab. 2009 Apr;11(4):405.

PMID:
19125777
20.

Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.

Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M.

Exp Clin Endocrinol Diabetes. 2008 Jan;116(1):6-13. Epub 2007 Dec 20.

PMID:
18095238

Supplemental Content

Support Center